Effects of the Prostacyclin Analogue ZK 36.374 on Cardiovascular Performance, Platelet Aggregation, and Plasmatic Coagulation during Hemodialysis

Author(s):  
G. Schultze ◽  
J. Heitz ◽  
E. Keller ◽  
T. Krais ◽  
H.-H. Neumayer ◽  
...  
1977 ◽  
Author(s):  
W. Kirch ◽  
H. Köhler

In some diseases, particularly in diseases of the vessels, there is a spontaneous aggregation of platelets. So it was of interest, whether in patients with diseases of the kidneys and essential hypertension there is a frequent spontaneous aggregation as well. In addition, the effect of the antithrombotic substance sulfinpyrazone on platelet aggregation, on plasmatic coagulation and on clinical parameters, for instance on proteinuria, was to be investigated. In 47 patients with diseases of the kidneys or essential hypertension spontaneous platelet aggregation, thrombin time, partial thromboplastin time, fibrinogen and factor VIII were studied. Patients with spontaneous platelet aggregation were given 800 mg sulfinpyrazone daily for I to 6 months. In 15 of 16 patients with chronic glomerulonephritis (serum creatinine 0,7-2,0 mg%) and 13 of 14 patients with a chronic pyelonephritis (serum creatinine 0,8–1,7 mg%) spontaneous platelet aggregation was found as well. So in almost all patients with chronic glomerulonephritis and pyelonephritis a spontaneous aggregation was seen. The frequency of spontaneous platelet aggregation in patients with essential hypertension is likely to depend on the stage of hypertension. Spontaneous platelet aggregation did not return to normal in any of our patients on sulfinpyrazone and the substance had no influence on proteinuria, haematuria and leukocyturia in patients with diseases of the kidneys.


1983 ◽  
Vol 50 (03) ◽  
pp. 718-721 ◽  
Author(s):  
A R Saniabadi ◽  
G D O Lowe ◽  
J J F Belch ◽  
C D Forbes ◽  
C R M Prentice ◽  
...  

SummaryPlatelet aggregation was studied at 37° C in citrated whole human blood, using the Ultra Flo 100 Whole Blood Platelet Counter. Aggregation was measured as a fall in the number of single platelets following addition of an aggregating agent. At peak aggregation, the fall in the number of platelets induced by ADP (10 μM), collagen (1 μg/ml) or thrombin (0.2 U/ml) was about 90%. When blood was incubated with the prostacyclin- analogue ZK36374, the aggregation responses to ADP, collagen and thrombin were reduced with IC50’S = 0.5, 1.5 and 3 nM respectively and the corresponding IC100’S were: 1, 3 and 12 nM. When ZK36374 was added at peak aggregation, the number of single platelets increased significantly due to disaggregation of preformed platelet aggregates. It is concluded that the present technique represents a rapid, sensitive and more physiological approach for investigating the effects of pharmacological agents on platelet aggregation.


1985 ◽  
Vol 53 (01) ◽  
pp. 090-094 ◽  
Author(s):  
A J Cowley ◽  
S Heptinstall ◽  
J R Hampton

SummaryPGI2 and ZK 36374 were each infused into volunteers and the effects on forearm blood flow and on platelet behaviour were determined. Infusions of PGI2 or ZK 36374 did not alter resting forearm blood flow but both agents reduced the extent of the vasoconstriction that occurred in response to cold. ZK 36374 appeared to be a much more potent inhibitor of platelet behaviour than PGI2 when blood was taken while the infusions were in progress, but the effects of both agents were no longer evident one hour after the infusions were terminated. There was an inverse relationship between the extent of cold-induced vasoconstriction and the concentration of sodium arachidonate that was needed to induce platelet aggregation for different individuals. Infusions of PGI2 affected both parameters equally but ZK 36374 had a greater effect on platelet behaviour than on blood flow. It is possible that very low doses of ZK 36374 would result in inhibition of platelet behaviour without producing adverse haemodynamic effects.


Author(s):  
W. H. Zucker ◽  
R. G. Mason

Platelet adhesion initiates platelet aggregation and is an important component of the hemostatic process. Since the development of a new form of collagen as a topical hemostatic agent is of both basic and clinical interest, an ultrastructural and hematologic study of the interaction of platelets with the microcrystalline collagen preparation was undertaken.In this study, whole blood anticoagulated with EDTA was used in order to inhibit aggregation and permit study of platelet adhesion to collagen as an isolated event. The microcrystalline collagen was prepared from bovine dermal corium; milling was with sharp blades. The preparation consists of partial hydrochloric acid amine collagen salts and retains much of the fibrillar morphology of native collagen.


Sign in / Sign up

Export Citation Format

Share Document